Product Description
Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7096576/)
Mechanisms of Action: ADR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TBS02 | P3 |
Suspended |
Asthma |
2025-12-01 |